Why AstraZeneca plc, Costain Group PLC And Sirius Minerals PLC Should Lag The FTSE 100 Today

AstraZeneca plc (LON: AZN), Costain Group PLC (LON: COST) and Sirius Minerals PLC (LON: SXX) all slip, on mixed news.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Is the FTSE 100 (FTSEINDICES: ^FTSE) going to end the week higher? Well, it was looking good yesterday, but the index of top UK stocks is down 20 points to 6,614 by late afternoon today, so things are not certain yet. Weak reports from some US companies, coupled with this morning’s news from Vodafone that things are still tough in Europe, have not raised optimism.

A number of individual shares are falling, too. Here are three from the various London indices that are on a bit of a slide today:

AstraZeneca

AstraZeneca (LSE: AZN) (NYSE: AZN.US) shares dipped 44p (1.4%) to 3,261p this morning after the company announced the completion of its acquisition of Omthera Pharmaceuticals, the developer of therapies for treating abnormal blood lipid levels. Today’s announcement told us that “the acquisition strengthens AstraZeneca’s late-stage cardiovascular disease pipeline” with Epanova, a fatty acid composition.

AstraZeneca paid $12.70 per share for a total cash cost of $323m, with Omthera shareholders also getting Contingent Value Rights up to the value of $120m dependent on specific targets for Epanova.

Costain

Infrastructure consultant and developer Costain Group (LSE: COST) saw its shares fall 7.6p (2.7%) to 279p, despite announcing a new £34m contract. The firm has been awarded an Early Contractor Involvement contract for a traffic improvement scheme in north Lincolnshire.

Costain shares are up 40% over the past 12 months, though there is fall in earnings per share forecast for the year to December 2013. But even with that, the shares are on a forward P/E of only around 11, with a 4% dividend yield expected.

Sirius Minerals

Things are getting gloomier by the day for Sirius Minerals (LSE: SXX) as details emerge concerning the deferral of the approval decision for the firm’s York Potash project. The big hurdle now appears to be a report prepared for the North York Moors National Park Authority, which questions the demand for polyhalite and the economic benefits claimed for the project.

For its part, Sirius believes that the report ignores some key economic issues and says that it has a number of healthy agreements for the sale of potash around the world. The Sirius share price responded with a 3.5p (16%) fall to 19p today, taking it down 31% since the start of the week.

Finally, reliable dividends can more than compensate for the day-to-day ups and downs of share prices. So how about a company that’s offering a 5% yield and which could be set for some nice share price appreciation too?

It’s the subject of our BRAND-NEW report, “The Motley Fool’s Top Income Share For 2013“, which you can get completely free of charge — but it will only be available for a limited period, so click here to get your copy today.

> Alan does not own any shares mentioned in this article. The Motley Fool has recommended shares in Vodafone.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Investing Articles

Now 70p, is £1 the next stop for the Vodafone share price?

The Vodafone share price is back to 70p, but it's a long way short of the 97p it hit in…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

If I’d put £5,000 in Nvidia stock at the start of 2024, here’s what I’d have now

Nvidia stock was a massive winner in 2023 as the AI chipmaker’s profits surged across the year. How has it…

Read more »

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »

Investing Articles

Barclays’ share price jumps 5% on Q1 news. Will it soon be too late to buy?

The Barclays share price has been having a great time this year, as a solid Q1 gives it another boost.…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

The AstraZeneca share price lifts 5% on a top-and-bottom earnings beat

The AstraZeneca share price reached £120 today and helped push the FTSE 100 higher. Would I still buy this flying…

Read more »